Targeting TFE3-fusion translocation RCC

The creation of a new patient-derived xenograft (PDX) model of TFE3-fusion translocation renal cell carcinoma (tRCC) has enabled the identification of dysregulated PI3K–AKT–mTOR signalling in this disease. Dual PI3K–mTOR inhibition had antitumour activity in vitro and in vivo, providing a novel line of enquiry for drug development for this difficult-to-treat malignancy.

Samples from a lymph node metastasis of micropthalmis transcription factor family tRCC were cultured in mice and then harvested to establish a cell line and for histological and molecular characterization. The resulting RP-R07 cells and PDXs retained the histological features of the original metastasis and had the same strong TFE3 nuclear immunoreactivity. RNA sequencing identified a fusion transcript spanning SFPQ and TFE3.

Analysis of the molecular pathways targeted by the SFPQTFE3 fusion gene showed that the PI3K–AKT–mTOR axis was consistently influenced, and many genes related to this pathway were identified as targets of the SFPQTFE3 fusion. Disproportionate upregulation of the PI3K–AKT–mTOR pathway was observed in three tRCC cell lines.

In vitro, testing of three vertical inhibition schemas to target the PI3K–AKT–mTOR axis showed that simultaneous inhibition of PI3K and mTOR with a dual inhibitor had more antiproliferative activity than PI3K–AKT or mTOR inhibition alone in tRCC. Silencing of TFE3 using small interfering RNA inhibited RP-R07 cell proliferation.

In vivo, treatment with a dual PI3K and mTOR inhibitor resulted in significantly lower RP-R07 PDX tumour weight than control treatment.

Overall, these data suggest that targeting the PI3K–AKT–mTOR axis has therapeutic potential in TFE3-fusion tRCC.


Original article

  1. Damayanti, N. P. et al. Therapeutic targeting of TFE3/IRS-1/PI3K/mTOR axis in translocation renal cell carcinoma. Clin. Cancer Res. (2018)

    Article  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Louise Stone.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Stone, L. Targeting TFE3-fusion translocation RCC. Nat Rev Urol 15, 658 (2018).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing